Hepatic primary stereotactic EBRT (eviQ ID 4024)

Endorsed eviQ protocol for stereotactic treatment of primary liver cancer (hepatocellular carcinoma or intrahepatic cholangiocarcinoma) in five fractions. It covers motion management (breath hold, free breathing with 4DCT, compression or gating), triple-phase contrast CT, fiducials (including lipiodol and surgical clips), contrast-enhanced MRI and rigid co-registration of MRI, PET and CT in the region of the liver. Its organ table draws on the LARK (TROG 17.03) trial protocol and the UK 2022 SABR consensus.

A liver SBRT protocol for hepatocellular carcinoma and intrahepatic cholangiocarcinoma, with detailed motion management, multiphase imaging, MRI and image co-registration guidance, and a full abdominal organ table.